Physiological structure and function of proteins

Cell Physiology Source Book

Volumn , Issue , 2012, Pages 19-47

  Pincus, Matthew ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882484352     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387738-3.00002-0     Document Type: Chapter

References (53)

1. Almoguerra C., Shibata D., Forrester K., Martin J., Arnheim M., Perucho M. Most human carcinomas of the endocrine pancreas contain mutant c-K- ras genes. Cell 1988, 53:813-815.
2. Anfinsen C.B., Haber E., Sela M., White F.H. The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain. Proc Natl Acad Sci USA 1961, 47:1309-1314.
3. Barbacid M. ras genes. Ann Rev Biochem 1987, 56:779-827.
4. Bargmann C.I., Weinberg R.A. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988, 7:2043-2052.
5. Ben-Levy R., Peles E., Goldman-Michael R., Yarden Y. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. J Biol Chem 1992, 267:17304-17313.
6. Blobel G., Walter P., Chang C.N., Goldman B.M., Erickson A.H., Lingappa R. Translocation of proteins across membranes: the signal hypothesis and beyond. Symp Soc Exp Biol 1979, 33:9-37.
7. Bogaart G.V.D., Guzman J.V., Mica J.T., Poolman B. On the mechanism of pore formation by melittin. J Biol Chem 2008, 283:33854-33857.
8. Brandt-Rauf P.W., Pincus M.R., Chen J.M. Conformational changes induced by the transforming amino acid substitution in the transmembrane domain of the neu-oncogene-encoded p185 protein. J Protein Chem 1989, 8:749-755.
9. Brandt-Rauf P.W., Rackovsky S., Pincus M.R. Correlation of the transmembrane domain of the neu-oncogene-encoded p185 protein with its function. Proc Natl Acad Sci USA 1990, 87:8660-8664.
10. Bull H.B. Physical Biochemistry 1943, John Wiley and Sons, London.
11. Caterall W.A. Structure and function of voltage-gated ion channels. Annu Rev Biochem 1995, 64:493-531.
12. Cho H.S., Mason K., Ramyar K.X., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
13. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O.S., King R., Aaronson S.A. erbB-2 is a potent oncogene when overex-pressed in NIH/3T3 cells. Science 1987, 237:178-182.
14. Downward J. Targeting the Ras signalling pathway in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
15. Dygert M., Go N., Scheraga H.A. Use of a symmetry condition to compute the conformation of gramicidin S. Macro-molecules 1975, 8:750-761.
16. Emr S.D., Silhavy T.J. Molecular components of the signal sequence that function in the initiation of protein export. J Cell Biol 1982, 95:689-696.
17. Engelman A.M., Steitz T.A. The spontaneous insertion of proteins into and across membranes: the helical hairpin hypothesis. Cell 1981, 23:411-422.
18. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003, 11:507-517.
19. Gibson K., Chin S., Pincus M.R., Clementi E., Scheraga H.A. Parallelism in conformational energy calculations on proteins: partial structure of interferon. Lecture Notes in Chemistry 1986, Vol. 44:198-213. M. Dupuis (Ed.).
20. Hall Z.W. Ion channels. An Introduction to Molecular Neurobiology 1992, 81-118. Sinauer Associates, Inc, Sunderland. Z.W. Hall (Ed.).
21. HER2 causes transformation and tumorigenesis of NIH/3T3 cells. Proc Natl Acad Sci USA 1987, 84:7159-7163.
22. James G.L., Goldstein G.L., Brown M.S., et al. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 1993, 260:1937-1942.
23. King C.F., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976.
24. Karplus M., McCammon The dynamics of proteins. Sci Am 1986, 254:42-52.
25. Kempf C., Klausner R.D., Weinstein J.N., van Renswoude J., Pincus M.R., Blumenthal R. Voltage-dependent transbilayer orientation of melittin. J Biol Chem 1982, 257:2469-2475.
26. Kussie P.H., Gorina S., Marechal V., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:921-922.
27. + channel. Science 2005, 309:897-903.
28. Miller M.H., Scheraga H.A. Calculation of the structure of collagen models. Role of interchain interactions in determining the triple helical coiled coil conformation. J Polymer Sci 1976, 54:171-200.
29. Monaco R., Chen J.M., Friedman F.K., Brandt-Rauf P.W., Pincus M.R. Structural effects of the binding of GTP to the wild-type and oncogenic forms of the ras-gene-encoded p21 proteins. J Protein Chem 1995, 14:721-730.
30. Padhy L.C., Shih C., Cowing D., Finkelstein R., Weinberg R.A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982, 28:865-871.
31. Pincus M.R. The chain build-up procedure in computing the structures of biologically active polypeptides and proteins. Int J Quant Chem: Quant Biol Symp 1988, 15:209-220.
32. Pincus M.R., Klausner R.D. Prediction of the three-dimensional structure of the leader sequence of murine pre-kappa light chain, a hexadecapeptide. Proc Natl Acad Sci USA 1982, 79:3413-3417.
33. Pincus M.R., Scheraga H.A. Conformational analysis of biologically active polypeptides, with application to oncogenesis. Accnt Chem Res 1985, 18:372-379.
34. Pincus M.R., Klausner R.D., Scheraga H.A. Calculation of the three-dimensional structure of the membrane-bound portion of melittin from its amino acid sequence. Proc Natl Acad Sci USA 1982, 79:5107-5110.
35. Pincus M.R., Brandt-Rauf P.W., Michl J., Friedman F.K. ras-p21-induced cell transformation: unique signal transduction pathways and implications for the design of new chemotherapeutic agents. Cancer Invest 2000, 18:39-50.
36. Pincus M.R., Brandt-Rauf P.W., Bluth M. Oncoproteins and early tumor detection. Henry's Clinical Diagnosis and Management by Laboratory Methods 2006, 1367-1380. Elsevier, Philadelphia. 21st ed. R. McPherson, M.R. Pincus (Eds.).
37. Pincus M.R., Michl J., Bowne W., Zenilman M. Anti-cancer peptides from the ras-p21 and p53 proteins. Research Advances in Cancer 2007, 65-90. Global Research Network Publishers, Kerala, India. R.M. Mohan (Ed.).
38. Rosale R., Pincus M.R., Brandt-Rauf P.W., Fine R.L., Michl J., Wang H. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry 2004, 43:1754-1861.
39. Rosenblatt M., Beaudette N.V., Fasman G.D. Conformational studies of the synthetic precursor-specific region of preproparathyroid hormone. Proc Natl Acad Sci USA 1980, 77:3983-3987.
40. Russell S.T., Warshel A. Calculations of electrostatic energies in proteins. The energetics of ionized groups in bovine pancreatic trypsin inhibitor. J Mol Biol 1985, 185:389-404.
41. Sarafraz-Yazdi E., Bowne W.B., Adler V., et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA 2010, 107:1918-1923.
42. Scheraga H.A. Protein structure and function, from a colloidal to a molecular point of view. Carlsberg Res Commun 1984, 49:1-55.
43. Scheraga H.A. Calculations of stable conformations of polypeptides, proteins, and protein complexes. Chim Scripta 1989, 29A:3-13.
44. Scheraga H.A., Liwo A., Oldziej S., et al. The protein folding problem:global optimization of force fields. Front Biosci 2004, 9:3296-3323.
45. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987, 235:177-182.
46. Tamba Y., Arivama H., Levadny V., Yamazaki M. Kinetic pathway of antimicrobial peptide magainin 2-induced pore formation in lipid membranes. J Phys Chem B 2010, 114:2018-2026.
47. Terwilliger T.C., Weissman L., Eisenberg D. The structure of melittin in the form I crystals and its implication for melittin's lytic and surface activities. Biophys J 1982, 37:353-361.
48. van Holde K.E. Physical Biochemistry 1985, Prentice Hall, Inc., Englewood Cliffs.
49. Vasquez M., Nemethy G., Scheraga H.A. Conformational energy calculations on polypeptides and proteins. Chem Rev 1994, 94:2183-2239.
50. Vogel H., Jahnig F. The structure of melittin in membranes Biophys J 1986, 50:573-582.
51. Willumsen B.M., Christensen A., Humbert N.L., Papageorge A.G., Lowy D.R. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984, 310:583-586.
52. Wuthrich K. NMR of Proteins and Nucleic Acids 1986, John Wiley and Sons, New York.
53. Yang L., Weiss T.M., Lehrer R.I., Huang H.W. Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J 2000, 79:2002-2009.